세계의 요실금 치료 시장 : 산업 분석, 규모, 점유율, 성장, 동향 예측(2024-2031년)

Persistence Market Research has recently released a comprehensive report on the worldwide market for urinary incontinence therapeutics. The report provides an in-depth analysis of key market dynamics, including drivers, trends, opportunities, and challenges, offering detailed insights into the market structure.

Key Insights:

• Urinary Incontinence Therapeutics Market Size (2024E): US$4.4 Bn
• Projected Market Value (2031F): US$5.8 Bn
• Global Market Growth Rate (CAGR 2024 to 2031): 4.1%

Urinary Incontinence Therapeutics Market - Report Scope:

Urinary incontinence therapeutics encompass a range of treatments designed to manage and alleviate symptoms of urinary incontinence, a condition affecting a substantial portion of the global population. These therapeutics include pharmacological treatments, surgical interventions, and non-pharmacological management strategies. The market caters to hospitals, clinics, urology centers, and homecare settings, offering a variety of therapeutic options, including anticholinergics, beta-3 adrenergic agonists, surgical devices, and pelvic floor muscle training.

Market Growth Drivers:

The global urinary incontinence therapeutics market is driven by several key factors, including the rising prevalence of urinary incontinence among the aging population and increasing awareness about available treatment options. Advances in therapeutic technologies, such as minimally invasive surgical techniques and novel pharmacological agents, are enhancing treatment efficacy and patient satisfaction. Additionally, the growing adoption of lifestyle modifications and behavioral therapies, along with increasing healthcare expenditures, is fueling market expansion.

Market Restraints:

Despite positive growth prospects, the urinary incontinence therapeutics market faces challenges related to high treatment costs, limited insurance coverage, and variability in patient response to different therapies. The high cost of advanced surgical procedures and long-term pharmacological treatments can be a barrier to market accessibility, particularly in emerging economies with constrained healthcare budgets. Moreover, regulatory hurdles and stringent approval processes for new therapeutics contribute to market entry barriers, affecting the pace of innovation and market growth.

Market Opportunities:

The urinary incontinence therapeutics market presents significant opportunities driven by ongoing research and development, demographic shifts, and evolving treatment paradigms. Innovations in drug formulations, such as extended-release and combination therapies, offer improved patient compliance and therapeutic outcomes. The integration of digital health technologies, including mobile health applications and telemedicine, enhances patient access to treatment and follow-up care. Furthermore, strategic partnerships, investment in clinical trials, and the development of cost-effective treatment solutions are crucial to capitalizing on emerging opportunities and sustaining market growth.

Key Questions Answered in the Report:

• What are the primary factors driving the growth of the urinary incontinence therapeutics market globally?
• Which therapeutic types and treatment modalities are leading the adoption of urinary incontinence therapies across different healthcare settings?
• How are technological advancements reshaping the competitive landscape of the urinary incontinence therapeutics market?
• Who are the key players contributing to the urinary incontinence therapeutics market, and what strategies are they employing to maintain market relevance?
• What are the emerging trends and future prospects in the global urinary incontinence therapeutics market?

Competitive Intelligence and Business Strategy:

Leading players in the global urinary incontinence therapeutics market, including Pfizer Inc., Astellas Pharma Inc., Allergan plc, and Medtronic plc, focus on innovation, product differentiation, and strategic collaborations to gain a competitive edge. These companies invest in R&D to develop advanced therapeutic solutions, including novel drug formulations and innovative surgical devices, catering to diverse patient needs and clinical requirements. Partnerships with healthcare providers, regulatory agencies, and research institutions facilitate market access and promote technology adoption. Emphasis on clinical research, patient education, and personalized treatment approaches drives market growth and enhances patient outcomes in the evolving urinary incontinence therapeutics landscape.

Key Companies Profiled:

• Pfizer Inc.
• Astellas Pharma Inc.
• Allergan plc
• Medtronic plc
• Boston Scientific Corporation
• Coloplast A/S
• Urovant Sciences Ltd.
• Santen Pharmaceutical Co., Ltd.
• Endo International plc
• Kaken Pharmaceutical Co., Ltd.

Urinary Incontinence Therapeutics Industry Segmentation

By Type

• Urge Incontinence
• Overflow Incontinence
• Stress Incontinence
• Functional Incontinence

By Drug Class

• Anticholinergics
• Beta-3 Adrenoceptor Agonists
• Alpha Blockers
• Estrogen
• Desmopressin
• Tricyclic Antidepressants

By End User

• Hospitals
• Retail Pharmacy
• Online Pharmacy

By Region

• North America
• Europe
• East Asia
• South Asia & Oceania
• Latin America
• The Middle East & Africa

Table of Contents

1. Executive Summary

• 1.1. Urinary Incontinence Therapeutics Market Snapshot, 2024-2031
• 1.2. Market Opportunity Assessment, 2024-2031, US$ Mn
• 1.3. Key Market Trends
• 1.4. Future Market Projections
• 1.5. Premium Market Insights
• 1.6. Industry Developments and Key Market Events
• 1.7. PMR Analysis and Recommendations

2. Market Overview

• 2.1. Market Scope and Definition
• 2.2. Market Dynamics
  • 2.2.1. Drivers
  • 2.2.2. Restraints
  • 2.2.3. Opportunity
  • 2.2.4. Challenges
  • 2.2.5. Key Trends
• 2.3. Macro-Economic Factors
  • 2.3.1. Global Sectorial Outlook
  • 2.3.2. Global GDP Growth Outlook
  • 2.3.3. Global Healthcare Spending Outlook
• 2.4. COVID-19 Impact Analysis
• 2.5. Forecast Factors - Relevance and Impact

3. Value Added Insights

• 3.1. Drug Type Adoption Analysis
• 3.2. Regulatory Landscape
• 3.3. Value Chain Analysis
  • 3.3.1. List of End-user/Marketplaces
    • 3.3.1.1. Retail
    • 3.3.1.2. Audiology
    • 3.3.1.3. E-Commerce
  • 3.3.2. List of End User (Industry)
• 3.4. Key Deals and Mergers
• 3.5. PESTLE Analysis
• 3.6. Porter's Five Force Analysis

4. Urinary Incontinence Therapeutics Market Outlook: Historical (2019-2023) and Forecast (2024-2031)

• 4.1. Key Highlights
  • 4.1.1. Market Size (US$ Bn) and Y-o-Y Growth
  • 4.1.2. Absolute $ Opportunity
• 4.2. Market Size (US$ Bn) Analysis and Forecast
  • 4.2.1. Historical Market Size (US$ Bn) Analysis, 2019-2023
  • 4.2.2. Current Market Size (US$ Bn) Analysis and Forecast, 2024-2031
• 4.3. Urinary Incontinence Therapeutics Market Outlook: Type
  • 4.3.1. Introduction / Key Findings
  • 4.3.2. Historical Market Size (US$ Bn) Analysis, By Type, 2019-2023
  • 4.3.3. Current Market Size (US$ Bn) Analysis and Forecast, By Type, 2024-2031
    • 4.3.3.1. Urge Incontinence
    • 4.3.3.2. Overflow Incontinence
    • 4.3.3.3. Stress Incontinence
    • 4.3.3.4. Functional Incontinence
    • 4.3.3.5. Other
• 4.4. Market Attractiveness Analysis: Type
• 4.5. Urinary Incontinence Therapeutics Market Outlook: Drug Class
  • 4.5.1. Introduction / Key Findings
  • 4.5.2. Historical Market Size (US$ Bn) Analysis, By Drug Class, 2019-2023
  • 4.5.3. Current Market Size (US$ Bn) Analysis and Forecast, By Drug Class, 2024-2031
    • 4.5.3.1. Anticholinergics
    • 4.5.3.2. Beta-3 Adrenoceptor Agonists
    • 4.5.3.3. Alpha Blockers
    • 4.5.3.4. Estrogen
    • 4.5.3.5. Desmopressin
    • 4.5.3.6. Tricyclic Antidepressants
    • 4.5.3.7. Other
• 4.6. Market Attractiveness Analysis: Drug Class
• 4.7. Urinary Incontinence Therapeutics Market Outlook: End-user
  • 4.7.1. Introduction / Key Findings
  • 4.7.2. Historical Market Size (US$ Bn) Analysis, By End-user, 2019-2023
  • 4.7.3. Current Market Size (US$ Bn) Analysis and Forecast, By End-user, 2024-2031
    • 4.7.3.1. Hospitals
    • 4.7.3.2. Retail Pharmacy
    • 4.7.3.3. Online Pharmacy
• 4.8. Market Attractiveness Analysis: End-user

5. Urinary Incontinence Therapeutics Market Outlook: Region

• 5.1. Key Highlights
• 5.2. Historical Market Size (US$ Bn) Analysis, By Region, 2019-2023
• 5.3. Current Market Size (US$ Bn) Analysis and Forecast, By Region, 2024-2031
  • 5.3.1. North America
  • 5.3.2. Europe
  • 5.3.3. East Asia
  • 5.3.4. South Asia and Oceania
  • 5.3.5. Latin America
  • 5.3.6. Middle East & Africa
• 5.4. Market Attractiveness Analysis: Region

6. North America Urinary Incontinence Therapeutics Market Outlook: Historical (2019-2023) and Forecast (2024-2031)

• 6.1. Key Highlights
• 6.2. Pricing Analysis
• 6.3. Historical Market Size (US$ Bn) Analysis, By Market, 2019-2023
  • 6.3.1. By Country
  • 6.3.2. By Type
  • 6.3.3. By Drug Class
  • 6.3.4. By End-user
• 6.4. Current Market Size (US$ Bn) Analysis and Forecast, By Country, 2024-2031
  • 6.4.1. U.S.
  • 6.4.2. Canada
• 6.5. Current Market Size (US$ Bn) Analysis and Forecast, By Type, 2024-2031
  • 6.5.1. Urge Incontinence
  • 6.5.2. Overflow Incontinence
  • 6.5.3. Stress Incontinence
  • 6.5.4. Functional Incontinence
  • 6.5.5. Other
• 6.6. Current Market Size (US$ Bn) Analysis and Forecast, By Drug Class, 2024-2031
  • 6.6.1. Anticholinergics
  • 6.6.2. Beta-3 Adrenoceptor Agonists
  • 6.6.3. Alpha Blockers
  • 6.6.4. Estrogen
  • 6.6.5. Desmopressin
  • 6.6.6. Tricyclic Antidepressants
  • 6.6.7. Other
• 6.7. Current Market Size (US$ Bn) Analysis and Forecast, By End-user, 2024-2031
  • 6.7.1. Hospitals
  • 6.7.2. Retail Pharmacy
  • 6.7.3. Online Pharmacy
• 6.8. Market Attractiveness Analysis

7. Europe Urinary Incontinence Therapeutics Market Outlook: Historical (2019-2023) and Forecast (2024-2031)

• 7.1. Key Highlights
• 7.2. Pricing Analysis
• 7.3. Historical Market Size (US$ Bn) Analysis, By Market, 2019-2023
  • 7.3.1. By Country
  • 7.3.2. By Type
  • 7.3.3. By Drug Class
  • 7.3.4. By End-user
• 7.4. Current Market Size (US$ Bn) Analysis and Forecast, By Country, 2024-2031
  • 7.4.1. Germany
  • 7.4.2. France
  • 7.4.3. U.K.
  • 7.4.4. Italy
  • 7.4.5. Spain
  • 7.4.6. Russia
  • 7.4.7. Turkey
  • 7.4.8. Rest of Europe
• 7.5. Current Market Size (US$ Bn) Analysis and Forecast, By Type, 2024-2031
  • 7.5.1. Urge Incontinence
  • 7.5.2. Overflow Incontinence
  • 7.5.3. Stress Incontinence
  • 7.5.4. Functional Incontinence
  • 7.5.5. Other
• 7.6. Current Market Size (US$ Bn) Analysis and Forecast, By Drug Class, 2024-2031
  • 7.6.1. Anticholinergics
  • 7.6.2. Beta-3 Adrenoceptor Agonists
  • 7.6.3. Alpha Blockers
  • 7.6.4. Estrogen
  • 7.6.5. Desmopressin
  • 7.6.6. Tricyclic Antidepressants
  • 7.6.7. Other
• 7.7. Current Market Size (US$ Bn) Analysis and Forecast, By End-user, 2024-2031
  • 7.7.1. Hospitals
  • 7.7.2. Retail Pharmacy
  • 7.7.3. Online Pharmacy
• 7.8. Market Attractiveness Analysis

8. East Asia Urinary Incontinence Therapeutics Market Outlook: Historical (2019-2023) and Forecast (2024-2031)

• 8.1. Key Highlights
• 8.2. Pricing Analysis
• 8.3. Historical Market Size (US$ Bn) Analysis, By Market, 2019-2023
  • 8.3.1. By Country
  • 8.3.2. By Type
  • 8.3.3. By Drug Class
  • 8.3.4. By End-user
• 8.4. Current Market Size (US$ Bn) Analysis and Forecast, By Country, 2024-2031
  • 8.4.1. China
  • 8.4.2. Japan
  • 8.4.3. South Korea
• 8.5. Current Market Size (US$ Bn) Analysis and Forecast, By Type, 2024-2031
  • 8.5.1. Urge Incontinence
  • 8.5.2. Overflow Incontinence
  • 8.5.3. Stress Incontinence
  • 8.5.4. Functional Incontinence
  • 8.5.5. Other
• 8.6. Current Market Size (US$ Bn) Analysis and Forecast, By Drug Class, 2024-2031
  • 8.6.1. Anticholinergics
  • 8.6.2. Beta-3 Adrenoceptor Agonists
  • 8.6.3. Alpha Blockers
  • 8.6.4. Estrogen
  • 8.6.5. Desmopressin
  • 8.6.6. Tricyclic Antidepressants
  • 8.6.7. Other
• 8.7. Current Market Size (US$ Bn) Analysis and Forecast, By End-user, 2024-2031
  • 8.7.1. Hospitals
  • 8.7.2. Retail Pharmacy
  • 8.7.3. Online Pharmacy
• 8.8. Market Attractiveness Analysis

9. South Asia & Oceania Urinary Incontinence Therapeutics Market Outlook: Historical (2019-2023) and Forecast (2024-2031)

• 9.1. Key Highlights
• 9.2. Pricing Analysis
• 9.3. Historical Market Size (US$ Bn) Analysis, By Market, 2019-2023
  • 9.3.1. By Country
  • 9.3.2. By Type
  • 9.3.3. By Drug Class
  • 9.3.4. By End-user
• 9.4. Current Market Size (US$ Bn) Analysis and Forecast, By Country, 2024-2031
  • 9.4.1. India
  • 9.4.2. Southeast Asia
  • 9.4.3. ANZ
  • 9.4.4. Rest of South Asia & Oceania
• 9.5. Current Market Size (US$ Bn) Analysis and Forecast, By Type, 2024-2031
  • 9.5.1. Urge Incontinence
  • 9.5.2. Overflow Incontinence
  • 9.5.3. Stress Incontinence
  • 9.5.4. Functional Incontinence
  • 9.5.5. Other
• 9.6. Current Market Size (US$ Bn) Analysis and Forecast, By Drug Class, 2024-2031
  • 9.6.1. Anticholinergics
  • 9.6.2. Beta-3 Adrenoceptor Agonists
  • 9.6.3. Alpha Blockers
  • 9.6.4. Estrogen
  • 9.6.5. Desmopressin
  • 9.6.6. Tricyclic Antidepressants
  • 9.6.7. Other
• 9.7. Current Market Size (US$ Bn) Analysis and Forecast, By End-user, 2024-2031
  • 9.7.1. Hospitals
  • 9.7.2. Retail Pharmacy
  • 9.7.3. Online Pharmacy
• 9.8. Market Attractiveness Analysis

10. Latin America Urinary Incontinence Therapeutics Market Outlook: Historical (2019-2023) and Forecast (2024-2031)

• 10.1. Key Highlights
• 10.2. Pricing Analysis
• 10.3. Historical Market Size (US$ Bn) Analysis, By Market, 2019-2023
  • 10.3.1. By Country
  • 10.3.2. By Type
  • 10.3.3. By Drug Class
  • 10.3.4. By End-user
• 10.4. Current Market Size (US$ Bn) Analysis and Forecast, By Country, 2024-2031
  • 10.4.1. Brazil
  • 10.4.2. Mexico
  • 10.4.3. Rest of Latin America
• 10.5. Current Market Size (US$ Bn) Analysis and Forecast, By Type, 2024-2031
  • 10.5.1. Urge Incontinence
  • 10.5.2. Overflow Incontinence
  • 10.5.3. Stress Incontinence
  • 10.5.4. Functional Incontinence
  • 10.5.5. Other
• 10.6. Current Market Size (US$ Bn) Analysis and Forecast, By Drug Class, 2024-2031
  • 10.6.1. Anticholinergics
  • 10.6.2. Beta-3 Adrenoceptor Agonists
  • 10.6.3. Alpha Blockers
  • 10.6.4. Estrogen
  • 10.6.5. Desmopressin
  • 10.6.6. Tricyclic Antidepressants
  • 10.6.7. Other
• 10.7. Current Market Size (US$ Bn) Analysis and Forecast, By End-user, 2024-2031
  • 10.7.1. Hospitals
  • 10.7.2. Retail Pharmacy
  • 10.7.3. Online Pharmacy
• 10.8. Market Attractiveness Analysis

11. Middle East & Africa Urinary Incontinence Therapeutics Market Outlook: Historical (2019-2023) and Forecast (2024-2031)

• 11.1. Key Highlights
• 11.2. Pricing Analysis
• 11.3. Historical Market Size (US$ Bn) Analysis, By Market, 2019-2023
  • 11.3.1. By Country
  • 11.3.2. By Type
  • 11.3.3. By Drug Class
  • 11.3.4. By End-user
• 11.4. Current Market Size (US$ Bn) Analysis and Forecast, By Country, 2024-2031
  • 11.4.1. GCC Countries
  • 11.4.2. Egypt
  • 11.4.3. South Africa
  • 11.4.4. Northern Africa
  • 11.4.5. Rest of Middle East & Africa
• 11.5. Current Market Size (US$ Bn) Analysis and Forecast, By Type, 2024-2031
  • 11.5.1. Urge Incontinence
  • 11.5.2. Overflow Incontinence
  • 11.5.3. Stress Incontinence
  • 11.5.4. Functional Incontinence
  • 11.5.5. Other
• 11.6. Current Market Size (US$ Bn) Analysis and Forecast, By Drug Class, 2024-2031
  • 11.6.1. Anticholinergics
  • 11.6.2. Beta-3 Adrenoceptor Agonists
  • 11.6.3. Alpha Blockers
  • 11.6.4. Estrogen
  • 11.6.5. Desmopressin
  • 11.6.6. Tricyclic Antidepressants
  • 11.6.7. Other
• 11.7. Current Market Size (US$ Bn) Analysis and Forecast, By End-user, 2024-2031
  • 11.7.1. Hospitals
  • 11.7.2. Retail Pharmacy
  • 11.7.3. Online Pharmacy
• 11.8. Market Attractiveness Analysis

12. Competition Landscape

• 12.1. Market Share Analysis, 2023
• 12.2. Market Structure
  • 12.2.1. Competition Intensity Mapping By Market
  • 12.2.2. Competition Dashboard
• 12.3. Company Profiles (Details - Overview, Financials, Strategy, Recent Developments)
  • 12.3.1. Pfizer Inc
    • 12.3.1.1. Overview
    • 12.3.1.2. Segments and Type
    • 12.3.1.3. Key Financials
    • 12.3.1.4. Market Developments
    • 12.3.1.5. Market Strategy
  • 12.3.2. AbbVie Inc.
  • 12.3.3. Astellas Pharma Inc.
  • 12.3.4. Johnson & Johnson
  • 12.3.5. Viatris Inc.
  • 12.3.6. Teva Pharmaceutical Industries Ltd.
  • 12.3.7. Sanofi S.A.
  • 12.3.8. GlaxoSmithKline plc
  • 12.3.9. Boehringer Ingelheim Pharmaceuticals, Inc.
  • 12.3.10. Bayer AG
  • 12.3.11. Ferring Pharmaceuticals

13. Appendix

• 13.1. Research Methodology
• 13.2. Research Assumptions
• 13.3. Acronyms and Abbreviations